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Abstract
Background: Off-target binding in the choroid plexus (CP) may cause spill-in of the tau PET tracer [18F] flortaucipir
into the adjacent hippocampus region. The impact of this spill-in on hippocampal uptake was assessed using a
novel partial volume correction method (PVC).
Methods: PVC was performed on 20 [18F] flortaucipir dynamic PET scans (10 probable AD and 10 controls).
Volumes of interest (VOIs) were defined for both hippocampus and CP. The correlation between hippocampal and
CP distribution volume (VT), with and without PVC, was determined. Both anatomically defined and eroded VOIs
were used.
Results: For controls, the correlation between hippocampal and CP VT was significantly reduced after using PVC
along with an eroded VOI (r2 = 0.59, slope = 0.80 versus r2 = 0.15, slope = 0.15; difference: p < 0.05). The same was
true for AD patients (p < 0.05).
Conclusion: PVC together with an optimized hippocampal VOI resulted in effective reduction of CP spill-in and
improved accuracy of hippocampal VT.
Introduction
The PET tracer [18F]flortaucipir([18F]AV-1451) is a
promising biomarker for in vivo assessment of tau path-
ology in AD [1]. However, cautious interpretation of
[18F] flortaucipir data is warranted, especially in the
hippocampus. Indeed, although tau pathology affects the
hippocampus relatively early in the course of the disease
[2], [18F] flortaucipir uptake in the hippocampus does
not distinguish AD patients from controls [3, 4]. A pos-
sible explanation may be that the relatively low spatial
resolution of PET leads to an underestimation of the sig-
nal in a small volume of interest (VOI) such as that of
the hippocampus [4], especially in case of atrophy [3].
Resulting partial volume effects (PVE) may cause spill-in
or spill-out to adjacent regions with higher or lower
activity, respectively [5]. In the hippocampal region, this
could also be the case as high off-target binding in the
adjacent choroid plexus (CP) [6] may cause spill-in of
[18F] flortaucipir [3, 7].
Partial volume correction (PVC) methods are used to
correct for PVE. Previous studies used several different
MR-based PVC methods [8–11] to process [18F] flortau-
cipir scans [7, 11–17]. Although some studies reported
no significant effects of PVC on the correlation between
tau uptake and cerebrospinal fluid (CSF) measures, cog-
nition, and diagnostic accuracy [13, 15, 17], the specific
impact of the CP signal on hippocampal [18F] flortauci-
pir uptake has yet to be evaluated.
In this study, PVC was performed using a method that
combines Van Cittert (VC) iterative deconvolution
(IDM) with highly constrained back-projection (HYPR)
denoising. The combination of HYPR and VC IDM
(Hypr-IDM-Hypr, HDH) was recently developed and
validated [18] and allows for more accurate
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quantification of PET images. The purpose of the
present study was to assess the impact of CP activity on
quantification of hippocampal [18F] flortaucipir binding
and to correct for spill-in using HDH PVC.
Methods
Participants
Ten patients with probable AD [19] and 10 cognitively
healthy controls from the Amsterdam Dementia Cohort
of the VU University Medical Center were included.
Probable AD patients were only included if they had a
positive [18F] florbetaben (amyloid-β) PET scan (visually
read) and/or an AD-like CSF profile [19–21]. All sub-
jects underwent the same study protocol as described
before [22]. The study protocol was approved by the
Medical Ethics Review Committee of the VU University
Medical Center. The data were acquired for a prospect-
ive study that was focused on model evaluation.
Data acquisition
All subjects underwent 3D-T1 weighted and FLAIR
scans on a 3.0 Tesla MR scanner (Ingenuity TF PET/
MR, Philips Medical Systems, Best, The Netherlands).
Dynamic PET emission scans were acquired using a
Philips Gemini TF-64 PET/CT scanner. The protocol
consisted of a dynamic scan of 130 min, after injection of
224 ± 18 MBq [18F] flortaucipir, with a 20-min break after
the first 60 min. Each part of the scanning period started
with a low-dose CT scan for attenuation correction [22].
Both continuous and manual arterial blood sampling
were performed [22], to obtain a metabolite corrected
plasma input function.
Data analysis
Partial volume correction
A recently described combination of HYPR denoising and
VC IDM was used to generate HDH PVC PET images (18).
The VC IDM was used for enhancing the spatial resolution
of the PET images. As the signal-to-noise ratio (SNR) also
reduces with each iteration, HYPR was used to limit the de-
crease in SNR, thereby preserving image quality.
Volumes-of-interest
The second session PET scan was co-registered to the
first session PET scan using VINCI (developed by S
Vollmar) [23] for motion correction between the two
sessions. Both T1-weighted and FLAIR MR images were
co-registered to the summed PET images (5 to 29
frames were used) using VINCI software. Hippocampal
VOI was defined in two different ways. First, the
complete hippocampal VOI was extracted from the
Hammers template [24] using PVElab [25] and the
T1-weighted MR images. The automatic delineation is
not perfect, and so even after PVC, it is possible that a
relationship between choroid plexus and hippocampus
might still persist because of the presence of the choroid
plexus region voxels in the hippocampal VOI definition.
Henceforth, for the second method, CP was defined
manually on HDH [18] PVC PET images and the MR
FLAIR image was used to crosscheck the VOI definition.
Next, the complete hippocampus VOI was superimposed
on the FLAIR image, and voxels from this VOI that were
in close vicinity of CP were removed from the VOI def-
inition, resulting in an “eroded” hippocampus VOI
(Additional file 1: Figure S1). Only voxels where CP
overlapped with the hippocampus were removed (~ 40%
± 10% of the total hippocampal voxels were removed).
For both methods, regional time activity curves (TACs)
were extracted by superimposing the VOIs onto all
frames of the PET scans.
Kinetic analysis
TACs were analyzed by non-linear regression (NLR)
using the two tissue compartment model with reversible
kinetics and blood volume fraction parameter
(2T4k_VB). It has previously been shown that this is the
preferred model to describe in vivo kinetics of [18F] flor-
taucipir [22, 26, 27]. Regional volume of distribution
(VT) was used as outcome measure.
Statistical analysis
Coefficients of determination (r2) and the slope of both
complete and eroded hippocampal VT with CP VT were
calculated. This analysis was performed with and with-
out PVC. In addition, interaction effects between hippo-
campal and CP VT were evaluated. The non-parametric
Wilcoxon signed rank test was used to calculate the dif-
ferences between methods. p < 0.05 was considered sta-
tistically significant. Statistical analysis was performed in
the GraphPad Prism 7.
Results
Ten controls (average age 67.7 ± 6.8 years, MMSE score
29.2 ± 0.6) and 10 probable AD patients (average age
63.9 ± 7.8 years, MMSE score 23.9 ± 3.1) were included.
There was no significant difference in age between AD
patients and controls (p < 0.05). Additional file 2: Figure
S2 illustrates the time activity curves for choroid plexus
and hippocampus VOIs (with and without PVC).
Before PVC, the relationship between the hippocam-
pus and CP in controls decreased for an eroded VOI
(r2 = 0.45, slope = 0.53) compared with the complete
VOI (r2 = 0.59, slope = 0.80). After PVC, a further de-
crease was observed for both complete VOI (r2 = 0.29,
slope = 0.27) and eroded VOI (r2 = 0.15, slope = 0.15).
The relationship between hippocampus and CP uptake
was significantly reduced when using an optimized VOI
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in combination with PVC (p for interaction < 0.05) (Fig. 2
and Additional file 3: Figure S3). An even stronger ef-
fect was observed in case of AD patients when using
PVC in combination with the optimized hippocampal
VOI (r2 = 0.54, slope = 0.98 without PVC versus r2 = 0.01,
slope = − 0.05 with PVC; p for interaction < 0.05)
(Figs. 1 and 2).
In addition, there was a significant decrease in hippocam-
pal VT after using both PVC and eroded VOI compared
with the uncorrected data (Fig. 3 and Additional file 4:
Figure S4, p < 0.05). VTs obtained for the choroid plexus
and hippocampus (complete and eroded) both before and
after PVC for all the subjects included in the study
(mean ± SD) are presented in the Additional file 5: Figure S5.
Discussion
In order to improve the quantification of [18F] flortauci-
pir uptake in the hippocampus, a novel HDH PVC
method was used together with an eroded hippocampal
VOI to correct for possible spill-in effects from the CP.
After PVC and optimizing hippocampal VOI, only a
weak correlation remained between hippocampal VT and
CP VT, suggesting that spill-in from the CP was success-
fully reduced thus allowing for more accurate quantifica-
tion of hippocampal [18F] flortaucipir uptake.
Wang et al. [16] showed that PVC [10] reduced the
correlation between [18F] flortaucipir hippocampal and
CP uptake (r = 0.39, p = 0.003 before PVC vs r = 0.14,
p = 0.31 after PVC). Wang et al. seem to have mitigated
the CP’s spill over without the use of hippocampal VOI
erosion. Although the PVC implementation used by
Wang et al. is not similar to the method used in this
study, it can be argued that the relationship between
choroid plexus and hippocampus is mitigated when ap-
plying PVC. With regard to the use of eroded hippocam-
pal VOI, the possible reason for Wang et al. to not
require erosion of hippocampal VOI could be that rela-
tionship present in their data between choroid plexus
and hippocampus was not as strong (r = 0.39) as in our
data (r = 0.76, combining both AD and controls). In case
of a weak relation, possibly just PVC is sufficient; how-
ever, in case of a stronger relation, erosion might be ne-
cessary. Another point to note is that before PVC, no
significant difference in the VTs was observed between
the complete hippocampal VOI and eroded hippocampal
VOI (Additional file 5: Figure S5). This suggests that the
benefit of erosion was only observed along with the PVC.
In addition, Schöll et al. [7] showed that PVC [8] caused a
large increase in CP signal, indicating that spill-out from
the CP could be reduced, potentially leading to a more ac-
curate estimation of tau uptake in the adjacent hippocam-
pus. Both studies suggest that PVC can be used to reduce
spill-over effects from the CP. Nevertheless, both studies
Fig. 1 Coronal [18F] flortaucipir VT images before (a) and after (b)
HDH PVC and coronal MR flair (c) in a healthy control (left) and probable
AD patient (right)
Fig. 2 Scatter plots illustrating the relationship between hippocampus VT and choroid plexus VT before (red) and after (blue) using both PVC and
an eroded hippocampal VOI for controls (left) and probable AD patients (right)
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used MR-based PVC methods, and segmentation prob-
lems could result in a potential bias [10].
One of the strengths of the present study is that the VC
IDM method leads to more accurate quantification of
PET images and does not use MR scans for PVC, thereby
avoiding potential segmentation and co-registration error.
The addition of HYPR reduces the poor SNR of VC IDM,
thus preserving image quality [18].
A potential weakness of this study is the fact that CP
VOI was defined on PVC PET images rather than on
MR images. However, CP activity could clearly be
distinguished from that of surrounding tissue, as it was
both visually and quantitatively much higher. Even then,
a manual VOI definition is prone to error and
inter-subject variability. In this study, the same re-
searcher worked on the VOI definition to avoid
inter-subject variability and to mitigate the error in VOI
definition, and the manual VOIs of CP on PET PVC im-
ages were validated using MR FLAIR images. PET
PVC-based VOI definitions showed good correspond-
ence to the MR FLAIR images, suggesting that PVC
PET images can be used for reliable definition of the CP
VOI; however, an automatic or a semiautomatic VOI
erosion method is warranted. Another limitation would
be that there is no ground truth (no autopsy data avail-
able) to check the accuracy of the implementation.
However, based on the presented analysis, it can be stated
that the proposed methodology mitigates the spill-over ef-
fects of choroid plexus on hippocampus uptake.
Conclusion
The use of our new PVC method in combination with
an optimized hippocampus VOI significantly reduces
spill-in of CP activity into the hippocampus and im-
proves accuracy of hippocampal VT.
Additional files
Additional file 1: Figure S1. Illustrates the eroded hippocampal VOI
definition on a T1 weighted MR scan of a subject (Sagittal slice). (TIF 680 kb)
Additional file 2: Figure S2. Time activity curves (TACs) of choroid
plexus and hippocampus VOI (with and without PVC). In case of hippocampal
VOI TACs for both complete and eroded VOI are presented. (TIF 475 kb)
Additional file 3: Figure S3. Relationship between the CP and
hippocampus when using only erosion or PVC alone. (TIF 208 kb)
Additional file 4: Figure S4. Spaghetti plots of hippocampus complete
VOI VT (no corrections) and after using either erosion (no corrections) or
PVC (complete VOI). (TIF 430 kb)
Additional file 5: Figure S5. Box plots (mean ± SD) for VTs obtained for
the choroid plexus and hippocampus (using complete VOI or Eroded VOI)
before and after PVC. (TIF 254 kb)
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